Every 8-K that Lineage Cell Therapeutics, Inc. (LCTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow LCTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LCTX filings page.
Lineage Cell Therapeutics reported second quarter 2026 results with total revenue of $1.1 million, down from $2.8 million a year earlier, mainly due to lower collaboration revenue under the Roche agreement and the prior termination of a VAC platform collaboration. Total operating expenses fell to $10.0 million from $22.5 million, reflecting the absence of a prior-year $14.8 million non-cash impairment charge. Loss from operations narrowed to $8.9 million from $19.8 million. Other income was $10.5 million versus other expense of $10.6 million, driven primarily by non-cash fair value remeasurement of warrant liabilities. Net income attributable to Lineage was $1.5 million, or $0.01 basic EPS, compared to a $30.5 million net loss in 2025.
Cash, cash equivalents and marketable securities totaled $50.8 million as of June 30, 2026, which the company expects will support planned operations into the third quarter of 2028. Operationally, Lineage highlighted positive three-year OpRegen data in geographic atrophy, advancement of COR1 for corneal endothelial disease into in‑vivo animal testing in 2026, ongoing OPC1 DOSED study enrollment, continued ILT1 manufacturing scale-up, preclinical progress in the ReSonance (ANP1) hearing loss program under a WDI collaboration, and the establishment of a Scientific Advisory Board.
Lineage Cell Therapeutics held its annual shareholder meeting, where investors elected seven directors to serve until the 2027 meeting. Each nominee, including CEO Brian M. Culley and Chair Angus C. Russell, received over 89.9 million votes in favor, with sizable broker non-votes.
Shareholders also ratified Baker Tilly US, LLP as independent auditor for the 2026 fiscal year and approved, on an advisory basis, the compensation program for named executive officers. Separately, Lineage withdrew its application for a CIRM CLIN2 grant for OPC1 but stated that this withdrawal does not affect its current or planned development of OPC1 in the ongoing DOSED spinal cord injury study.
Lineage Cell Therapeutics reported first quarter 2026 results showing modest revenue growth alongside higher R&D investment and continued strategic pipeline progress. Total revenue for the quarter ended March 31, 2026 was $1.7 million, up from $1.5 million a year earlier, mainly from a collaboration with William Demant Invest.
Total operating expenses rose to $9.3 million from $8.0 million, driven by increased R&D spending on OPC1, the ReSonance hearing-loss program, and other preclinical work. Net loss attributable to Lineage was $4.8 million, or $0.02 basic and $0.03 diluted per share, compared with a $4.1 million net loss in 2025.
The company ended the quarter with $53.4 million in cash, cash equivalents, and marketable securities, which it expects to fund planned operations into the second quarter of 2028. Operationally, Lineage highlighted positive three-year OpRegen data in geographic atrophy, treatment of a second chronic spinal cord injury patient with OPC1, launch of its COR1 corneal program, progress on its AlloSCOPE 5D/ILT1 manufacturing initiative, and the formation of a new Scientific Advisory Board and senior clinical leadership.
Lineage Cell Therapeutics, Inc. filed a new prospectus supplement to support an at-the-market offering of its common shares with an aggregate offering price of up to $60,000,000 through or to B. Riley Securities, Inc. This program is under an existing Form S-3 shelf registration and sales agreement framework and excludes $22,583,663.82 in common shares already sold under prior prospectus supplements.
Lineage Cell Therapeutics reported higher revenue but a much larger net loss for 2025 while extending its cash runway and advancing its cell therapy pipeline. Total revenues for the year ended December 31, 2025 were $14.6 million, up from $9.5 million in 2024, mainly from collaboration revenue with Roche and a new research collaboration with William Demant Invest.
Total operating expenses rose to $51.2 million, including a $14.8 million impairment of an intangible asset related to the VAC platform. A large non-cash fair value remeasurement expense of warrant liabilities contributed to other expense of $32.0 million, versus other income of $2.9 million in 2024. Net loss attributable to Lineage widened to $63.5 million, or $0.28 per share, compared to $18.6 million, or $0.09 per share.
As of December 31, 2025, cash, cash equivalents and marketable securities were $55.8 million. Together with approximately $5.4 million in warrant exercise proceeds in March 2026, management expects this to fund planned operations into the second quarter of 2028. Operationally, the company achieved its first OpRegen milestone under its collaboration with Roche and Genentech, reported positive 36‑month OpRegen Phase 1/2a data, demonstrated high-scale AlloSCOPE manufacturing, secured up to $12 million of planned ReSonance (ANP1) preclinical funding from William Demant Invest, and treated the first chronic spinal cord injury patient in the OPC1 DOSED study.
Lineage Cell Therapeutics reported that it has withdrawn its June 2025 application for a CLIN2 clinical trial grant from the California Institute for Regenerative Medicine, which was intended to support continued development of its OPC1 cell therapy for spinal cord injuries. The withdrawal followed CIRM comments on the application received in late November 2025.
The company states that CIRM did not identify specific content deficiencies in the application and that, after discussions with CIRM representatives, it plans to submit a revised application in the next grant cycle currently scheduled for January 2026. Lineage also notes that this withdrawal and planned resubmission do not affect its current or planned OPC1 development work or the ongoing DOSED clinical study using a novel spinal cord delivery device in subacute and chronic spinal cord injury participants.
Lineage Cell Therapeutics announced that it has achieved the first development milestone under its collaboration and license agreement with Genentech and F. Hoffmann-La Roche for OpRegen, its lead cell therapy program for geographic atrophy secondary to age-related macular degeneration. Meeting this milestone on November 20, 2025, based on manufacturing and clinical progress in the Phase 2a GAlette trial, triggers a $5 million milestone payment to Lineage, expected within 30 days. Lineage reports that approximately 24.1% of this payment will be paid to the Israel Innovation Authority and 21.5% to Hadasit Medical Research and Development Ltd., under existing Israeli research and collaboration agreements tied to its subsidiary Cell Cure Neuroscience Ltd.
Lineage Cell Therapeutics (LCTX) completed a capital raise. On November 12, 2025, the company sold 12,000,000 common shares to Janus Henderson Investors at $1.75 per share in a block transaction under its at-the-market program. The transaction generated $21 million in gross proceeds before fees and expenses.
This direct sale to a single institutional investor provides new cash to the company while increasing the share count. The pricing and size were fixed in the block trade, rather than dribbled out, which can offer execution certainty under an ATM framework.
Lineage Cell Therapeutics (LCTX) furnished an 8-K under Item 2.02 announcing financial results via a press release for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1. The company stated this information is being furnished, not filed, under the Exchange Act and will not be incorporated by reference except as expressly set forth by specific reference.
Lineage Cell Therapeutics disclosed a new multi-year research collaboration with William Demant Invest 2 Aps (WDI) to advance its auditory neuronal cell transplant program, ReSonance (ANPI), aimed at treating hearing loss. WDI has agreed to fund up to $12 million in research collaboration costs over an approximate three-year term.
The collaboration focuses on completing preclinical work so the program may be ready to progress to human clinical trials under future clinical agreements to be negotiated in good faith. Each party keeps ownership of its existing intellectual property, while Project Results will generally be jointly owned, with specific provisions allowing one party to buy out the other’s interest if it decides not to continue into clinical development.
On August 12, 2025, Lineage Cell Therapeutics furnished a press release announcing its financial results for the quarter ended June 30, 2025, which is provided as Exhibit 99.1. The Form 8-K states the information is being furnished, not filed, and therefore is not incorporated by reference into other filings. The filing also includes an Inline XBRL cover page as Exhibit 104. The report is signed by George A. Samuel III, General Counsel and Corporate Secretary.
Lineage Cell Therapeutics announced promising 36-month results from their Phase 1/2a clinical study of RG6501 (OpRegen®) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Key findings include:
- Visual Acuity Improvements: Cohort 4 patients (less advanced GA) showed sustained improvement through 36 months, with mean BCVA gains of +6.2 letters overall and +9.0 letters in patients with extensive OpRegen coverage
- Structural Improvements: Sustained retinal structural improvements observed through OCT analysis, with treated eyes maintaining RPEDC area (+1.9 mm²) while untreated eyes declined (-3.8 mm²)
- Current Development: A Phase 2a "GAlette" study (NCT05626114) is actively enrolling patients, testing new proprietary surgical devices for OpRegen delivery
The therapy is being developed through a worldwide collaboration between Lineage, Roche, and Genentech. Results suggest OpRegen cell therapy may provide durable support to remaining retinal cells within atrophic areas for at least 36 months after a single administration.